Qing Hai Zhao
Corporate Officer/Principal chez ADAGENE INC.
Profil
Qing Hai Zhao is currently the Chief Manufacturing Officer at Adagene, Inc. Prior to this, he held positions as Executive Director & Head-Chemistry at NGM Biopharmaceuticals, Inc., Vice President-Manufacturing at AnaptysBio, Inc., and VP-Technical Development & Manufacturing at Forty Seven, Inc. Zhao received a doctorate degree from the University of Uppsala in 1998, an undergraduate degree from East China University of Science & Technology in 1982, and a graduate degree from Zhongshan Hospital Fudan University.
Postes actifs de Qing Hai Zhao
| Sociétés | Poste | Début |
|---|---|---|
| ADAGENE INC. | Corporate Officer/Principal | 01/10/2020 |
Anciens postes connus de Qing Hai Zhao
| Sociétés | Poste | Fin |
|---|---|---|
| FORTY SEVEN, INC. | Corporate Officer/Principal | 01/10/2020 |
| ANAPTYSBIO, INC. | Corporate Officer/Principal | 01/01/2017 |
| NGM BIOPHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/01/2016 |
Formation de Qing Hai Zhao
| East China University of Science & Technology | Undergraduate Degree |
| University of Uppsala | Doctorate Degree |
| Zhongshan Hospital Fudan University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ADAGENE INC. | Health Technology |
| ANAPTYSBIO, INC. | Health Technology |
| NGM BIOPHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
